Clinical Experience with Venetoclax in Combination with Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
ConclusionCombination therapy with venetoclax shows promising clinical efficacy in R/R T-ALL. Further studies are warranted to evaluate the clinical benefit of BCL2 inhibitors in T-ALL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study